glp 1 and joint pain Glucagon-like peptide its receptor agonists for the treatment of rheumatic diseases GLP-1 Agonists In Obesity

Also, with up to 10 different pathways that could influence obesity and cardiovascular disease, the permutations are huge

In clinical trials, side effects tended to occur within the first weeks of starting therapy and with dose escalation, but they generally improved with time on a stable dose

These medicines work best when used as ongoing treatment, similar to medicine for high blood pressure or diabetes

Rather than applying uniform treatment protocols, were moving toward precision medicine that considers each patients unique metabolic fingerprint

Bone health monitoring is essential during GLP-1 therapy

PMC 5050443